Mifepristone, Marburg virus, new COVID variant and RSV ...
The AMA Update covers a range of health care topics affecting the lives of physicians and patients. Learn more about news on Mifepristone, new COVID variant and more.
www.ama-assn.orgI don’t have live access to current news sources in this moment, but I can summarize recent context and indicate where to check for the latest updates on mifepristone.
Core answer
- There has been ongoing federal review and legal activity around mifepristone in 2024–2026, including FDA safety data reviews, REMS discussions, and court rulings that have at times affected access. For the very latest developments, please consult major outlets’ health desks or official FDA statements.
Recent context to guide your search
- FDA reviews and safety assessments: In 2024–2025, U.S. health leaders signaled ongoing reviews of mifepristone safety data and dispensing conditions, with questions about access and how the drug is used in practice. Look for statements from the FDA and HHS, and coverage by CBS News, CNN, and Health outlets for direct quotes and timeline updates.[1][6][9]
- Legal and policy developments: There were publications noting court orders and state-level actions affecting REMS or distribution, and reports discussing how these rulings interact with nationwide access, including potential restrictions or protections for ongoing use in miscarriage management.[2][4][5][7]
- Public-health briefings and expert analysis: Medical associations and health-news programs have tracked how regulatory changes might influence telemedicine access, prescribing practices, and patient choice, with updates posted by AMA, CNN, and KFF Health News outlets.[7][9][2]
Where to check for the latest
- FDA official updates on mifepristone and REMS program status: fda.gov
- Reputable national outlets’ health desks:
- CBS News health section (FDA review updates)
- CNN health coverage on mifepristone and related court rulings
- KFF Health News and Bloomberg Law for policy and regulatory context
- Major medical associations’ statements or briefings (AMA, ACOG) for clinical implications
If you’d like, I can:
- Narrow down to a specific date range and pull the most relevant articles from major outlets.
- Create a quick brief listing key developments and their practical implications for patients in Illinois or Chicago.
- Provide a short explainer on what a REMS review could mean for access and how patients can stay informed.